Pediatric response to second-line antiretroviral therapy in South Africa - Wikidata - awgldk - TriplyDB

Pediatric response to second-line antiretroviral therapy in South Africa

Pediatric response to second-line antiretroviral therapy in South Africa

http://www.wikidata.org/entity/Q34490216

about

Sequencing paediatric antiretroviral therapy in the context of a public health approach Clinical, Virologic, Immunologic Outcomes and Emerging HIV Drug Resistance Patterns in Children and Adolescents in Public ART Care in Zimbabwe Getting to 90-90-90 in paediatric HIV: What is needed?Viral load versus CD4⁺ monitoring and 5-year outcomes of antiretroviral therapy in HIV-positive children in Southern Africa: a cohort-based modelling study Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study [Treatment failure in children infected with HIV in routine follow-up in a resource-limited setting in Cameroon]Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.Tackling virological failure in HIV-infected children living in Africa.Determinants of durability of first-line antiretroviral therapy regimen and time from first-line failure to second-line antiretroviral therapy initiation.Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure.Higher retention and viral suppression with adolescent-focused HIV clinic in South Africa Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand

P2860

Q26774261-E6D14FE2-20F3-4B05-B4F2-C3A6D18185B1 Q28551494-BC2294FD-0BE7-4C24-9547-B82E6E7CCB72 Q30385352-0F95A10F-F7A0-4B3A-BEF4-E36447228189 Q34508454-2B764D1F-514E-4792-A330-98B35EBFDA92 Q35156697-A6A87881-DB01-45D3-A114-C2E4DF81077E Q35955127-6C9FBA5D-F963-4A82-80CB-756E1354BC1D Q36063912-5DBEA075-7F12-4B6D-AE9A-317F314AAC43 Q36087922-661C872C-1E8A-4AE6-9342-310E3A23F712 Q37260613-4335E556-5861-4D2E-9778-1C47EA89FEE2 Q37722675-37A6C204-ACE3-40FE-9272-A33BC527E7AF Q38552894-95353F92-559A-4E0D-BE69-6661E39D8B94 Q41071212-82443314-1F1E-4F39-A842-CF41A86B6A37 Q41929466-448CD37F-A607-460B-8EAE-716CF224EB89 Q47008725-829B87DD-D24E-43E3-9898-66CDC5392D5C Q57077691-60BE1F67-32E2-4D11-8CA9-63F2AF30FB95

P2860

Pediatric response to second-line antiretroviral therapy in South Africa

http://www.wikidata.org/entity/Q34490216

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Pediatric response to second-line antiretroviral therapy in South Africa

@ast

Pediatric response to second-line antiretroviral therapy in South Africa

@en

Pediatric response to second-line antiretroviral therapy in South Africa

@nl

type

label

Pediatric response to second-line antiretroviral therapy in South Africa

@ast

Pediatric response to second-line antiretroviral therapy in South Africa

@en

Pediatric response to second-line antiretroviral therapy in South Africa

@nl

prefLabel

Pediatric response to second-line antiretroviral therapy in South Africa

@ast

Pediatric response to second-line antiretroviral therapy in South Africa

@en

Pediatric response to second-line antiretroviral therapy in South Africa

@nl

P1433

Q34490216-60A6C6E4-0020-4740-8025-3600C93492FC

P1476

Q34490216-8A8C0BAE-4977-4B49-AB25-6D61E8FB8935

P2093

Q34490216-439CAAE6-B6C6-4ED8-888A-C68C12BD71CD

Q34490216-85B6707A-1456-4F27-B51F-4FFEE7EAD238

Q34490216-C09A8F73-EB82-49C2-B4F3-216EBE2BDDC2

P2860

Q34490216-0A28C473-A27E-41F5-96E6-7DD4362B5A80

Q34490216-0D6B1670-745A-4FD3-BF81-E8888F2E376F

Q34490216-1204A2D8-E5B2-4989-BB93-811CC5C7BD04

Q34490216-145A24D4-B0FA-4EC7-82FE-43286DD33D4A

Q34490216-14969842-9BFE-4AF5-A166-AAEA9FA1F56C

Q34490216-242FFDA2-3332-40CD-8CF3-898DC20DDD3F

Q34490216-25B89020-951F-405C-898B-530D51F810D2

Q34490216-26DE579E-0ADA-4B06-9319-DBC3B23F8743

Q34490216-2B5CE19B-5FB5-46ED-817D-219C7C971464

Q34490216-3C6E9244-8201-44BB-A07B-7968F24F6AAC

P304

Q34490216-05E8FB72-3969-4D24-AECB-F97BD4695CC8

P31

Q34490216-AE3C346F-88FB-4B63-B38F-94E32676776D

P356

Q34490216-858E2FC9-1B70-4A99-8CD4-60362A3CD932

P407

Q34490216-B01196E4-8E0E-4ECE-9CC9-3DAE7AE6C76C

P433

Q34490216-314C7C55-C289-44EB-93FD-9C4EFB89FF65

P478

Q34490216-A9333268-63D0-4889-BFDD-A3A4AD3E70BF

P577

Q34490216-DAB96527-6486-48D2-8CD3-223FCF06B182

P5875

Q34490216-D2C600C5-77F4-4C5A-BE72-6803004B5D70

P698

Q34490216-AD5C00FF-D964-4EA9-8CDA-739C6CFDD83E

P921

Q34490216-67C0F2BA-BDE7-41DF-B002-8B815EB7DF22

Q34490216-6FA79CE6-A248-47D0-A8FC-48534E131A36

P932

Q34490216-B60DB6DE-98B3-487E-B096-F3CED8B2F351

P356

JOURNAL.PONE.0049591

P1433

P1476

Pediatric response to second-line antiretroviral therapy in South Africa

@en

P2093

Brian C Zanoni

http://www.w3.org/2001/XMLSchema#string

Henry Sunpath

http://www.w3.org/2001/XMLSchema#string

Margaret E Feeney

http://www.w3.org/2001/XMLSchema#string

P2860

Risk factors associated with increased mortality among HIV infected children initiating antiretroviral therapy (ART) in South Africa

Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study.

Antiretroviral treatment for children with peripartum nevirapine exposure.

Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.

First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.

Sex differences in HIV RNA level and CD4 cell percentage during childhood

Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.

Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.

Metabolic issues associated with protease inhibitors.

Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.

P304

e49591

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0049591

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233775548

http://www.w3.org/2001/XMLSchema#string

P698

23185373

http://www.w3.org/2001/XMLSchema#string

P921

Aafrikaa Kibbaa

antiretroviral drug

P932

3502491

http://www.w3.org/2001/XMLSchema#string